A comprehensive understanding of signaling pathways requires detailed knowledge regarding ligand-receptor interaction. This article describes two fast and reliable point-by-point protocols of enzyme-linked immunosorbent assays (ELISAs) for the investigation of ligand-receptor interactions: the direct ligand-receptor interaction assay (LRA) and the competition LRA. As a case study, the ELISA based analysis of the interaction between different lambda interferons (IFNLs) and the alpha subunit of their receptor (IL28RA) is presented: the direct LRA is used for the determination of dissociation constants (K D values) between receptor and IFN ligands, and the competition LRA for the determination of the inhibitory capacity of an oligopeptide, which was designed to compete with the IFNLs at their receptor binding site. Analytical steps to estimate K D and half maximal inhibitory concentration (IC 50 ) values are described. Finally, the discussion highlights advantages and disadvantages of the presented method and how the results enable a better molecular understanding of ligand-receptor interactions.
Introduction
A comprehensive understanding of signaling pathways requires detailed knowledge about the ligand-receptor interaction. Most methods for assessing the interaction of a particular ligand with its specific receptor are expensive, time consuming, labor intensive and require specific equipment and expertise 1 . This article describes two fast and reliable point-by-point protocols to investigate the ligand-receptor interaction based on an enzyme linked immunosorbent assay (ELISA): the direct ligand-receptor interaction assay (LRA) and the competition LRA. ELISA is a highly sensitive, specific and readily available technique, routinely used in almost every laboratory. ELISA can be performed and adapted in various fashions. The presented protocols are optimized for the investigation of the interaction between different lambda interferons (INFLs) and their receptor.
The direct LRA allows for a quantification of ligand-receptor binding with respect to ligand concentration and thus yields a binding curve. Using an appropriate model for the ligand-receptor interaction, the data can be further analyzed to estimate the dissociation constant (K D ).
ligands and receptors by using blocking peptides, which are designed to mimic either the ligand or the receptor. If the blocking peptide shows efficient and specific inhibition, the peptide occupies a critical interaction site of the ligand (if the peptide mimics the receptor) or of the ligand (if the peptide mimics the ligand).
The first protocol describes the K D value determination of different INFLs and the alpha subunit of their receptor, i.e., the interleukin-28 receptor (IL28RA) using the direct LRA. Next, the second protocol shows how to determine the capability of a 20 amino acid long peptide to inhibit the INFL-IL28RA interactions. The peptide is designed to compete with IFNLs at their receptor binding site and thus enables a molecular understanding of the interaction. Furthermore, this peptide can be used to block IL28RA in in vitro experiments to determine the impact on downstream signaling effects 4 .
Protocol

Reagent Preparation
1. To prepare carbonate coating buffer, dissolve 0.36 g Na 2 CO 3 and 0.84 g NaHCO 3 in 100 ml distilled water; sterile filter the buffer by using a vacuum driven 0.22 µm polyethersulfone (PES) membrane filter and store at RT until usage. 
Enzyme-linked Immunosorbent Assays (ELISAs)
NOTE: The direct ligand-receptor interaction ELISA (direct LRA, Figure 1 ) can be used to measure the receptor-ligand dissociation constant (K D ), as a measure of the receptor-ligand binding affinity. The competition ligand-receptor interaction ELISA (competition LRA, Figure 2 ) allows screening of peptides (and other blocking compounds), which act to interfere with the interaction between ligand and receptor. The basic protocol that was previously published 5 was further optimized.
NOTE: In both ELISA methods use multichannel pipette for adding solutions to the wells of 96-well plate in each step. In solution decant or washing steps, throw out the solutions directly into the sink. Block the free receptor-binding sites in the coated plate using 200 µl of 5% BSA solution to each well using a multichannel pipette and incubate the plate for 2 hr at RT. 3. Discard the blocking solution (see step 2.1.2.1.) and wash the plate 3 times with washing solution. 4. Prepare the recombinant His-tagged ligands at different concentrations (e.g., 8 µg/ml, 4 µg/ml, 2 µg/ml, 1 µg/ml, 0.5 µg/ml, 0.25 µg/ml, 0.125 µg/ml, 0.063 µg/ml, 0.031 µg/ml, 0.0 µg/ml) in PBS. Add only PBS in the blank wells. 5. Add 100 µl of each ligand concentration to the wells in duplicate and incubate the plate for 2 hr at RT allowing receptor-ligand interaction.
3. Step-by-step protocol for direct LRA. Please click here to view a larger version of this figure.
2. Competition Ligand-Receptor-Interaction Assay (competition LRA) NOTE: For an illustration of the workflow see Figure 2 . The competition LRA procedure follows the same steps as the direct LRA (coating the plate, antibody incubation, plate development) except for important changes in the ligand and peptides addition step. Proper negative controls are essential for this assay. In a previous screening study 4 , the scrambled blocking peptide did not show antagonistic effects. 
Discussion
ELISA is a standard and well-established method for many laboratories. We have further modified and improved a previously published method 5, 7 . The demonstrated step-by-step protocol shows how it can be used in a simple way to determine the K D values of ligand-receptor interactions. In addition, the IC50 of a blocking peptide that interferes with the ligand-receptor interaction can be determined.
Major advantages are the rapid setup, easy preparation of reagents and familiar handling, as most researchers have used an ELISA protocol before. The direct LRA protocol is highly flexible and can be adapted to measure many protein-protein interactions. Recombinant proteins with His6-or alternative tag should be used as the binding partner to an immobilized partner. The competition LRA can be exploited as a screening tool to (i) determine the inhibitory potential of blocking compounds (peptides, antibodies, or small molecules) and to (ii) determine the critical interaction sites by using blocking peptides designed to mimic the receptor or the ligand.
Negative controls are essential for a proper interpretation of the presented assays. In a previous screening study 4 , the scrambled sequence of the used blocking peptide did not show antagonistic effects. However, other peptides showed a blocking capacity also after scrambling, likely due to unspecific electrostatic interactions.
A potential limitation is that this assay reflects an in vitro situation. In particular, heterodimeric receptors often form a more complex structure. It is not possible to distinguish whether the ligand just binds to the receptor or whether the ligand also activates the receptor by triggering a conformational change or a dimerization, which in turn leads to an intracellular signal. In the presented assay, we used a recombinant receptor, which is immobilized to a solid phase. This setup does not work to test the activation or to investigate the interaction of receptors, which require the membrane environment or membrane cholesterol such as G protein coupled receptors (GPCRs). Also the use of recombinant protein raises caveats. For example, the folding and tertiary structure of a recombinant protein may be different compared to an in vivo situation. The binding of ligand and receptor usually occurs at RT, however in humans the optimal temperature would be 37 °C. Finally, the use of commercial recombinant ligand and receptor can prove expensive. Despite these limitations, these two ELISA protocols show potential to rapidly explore the ligand-receptor interaction.
The presented results show that IFNL1 has a slightly higher affinity for IL28RA compared to IFNL2, and the affinity of IFNL3 is three-fold lower than IFNL2. This is remarkable considering the similarity between IFNLs. IFNL1 and IFNL2 differ in 33 amino acids while IFNL2 and IFNL3 differ only in seven amino acids 8 . The interaction between IL28RA and IFNLs involves Helix A and the AB-loop of IFNL 9 . Alignment of IFNL sequences reveals four significant differences in Helix A and the AB-loop between IFNL1 and IFNL3 ( Figure 5A) . One affects the salt bridge Arg54-Glu119. The amino acid residues in this section are enumerated according to the UniProt entries Q8IU54 (IFNL1), Q8IZI9 (IFNL3), Q8IZJ0 (IFNL2) and Q8IU57 (IL28RA), which has been found in the crystal structure of the IFNL1-IL28R1 complex ( Figure 5B) . Structural alignment shows that Arg57 in IFNL1 is replaced by Lys57 in INFL3, which is also able to form a salt bridge with Glu118 ( Figure 5C) . Consistent with the decreased affinity of IFNL3 and IL28RA, computational 10, 11 and mutational 12 analyses show, that Lys-Glu salt bridges are in general less stable than Arg-Glu salt bridges.
However, the differences in Helix A do not satisfactorily explain the lower affinity of IFNL3, since the amino acid sequence of Helix A is identical for IFNL2 and IFNL3. It is thought that the main difference arises from the mutations in the AB-loop, where Arg74 and His76 in IFNL2 are replaced by Lys70 and Arg72 in IFNL3 8 .
Moreover, differences in stability and solubility between IFNLs may also affect the outcome of the assay. Since the direct LRA assay uses concentrations from nM to M and the physiological concentration of cytokines in serum lies in the pM to nM range, aggregation of IFNL cannot be excluded. We can assume that the observed positive cooperativity of the IFN binding is caused by a specific or non-specific increase in ligandreceptor binding, e.g., a dimerization of the recombinant IL28RA receptor in solution, or a binding of a second ligand or ligand fragment with higher affinity. However, further studies are required to verify this.
The blocking peptide used in the competition LRA mimics the AB-loop of IFNL3 ( Figure 6 ). As previously described, the AB-loop plays an essential role in the interaction between IFNLs and IL28RA
9
, particularly IFNL2 and IFNL3. Homology modeling of IFNL3 with the IL28RA/IFNL1 crystal structure shows that the region, which corresponds to the blocking peptide lies in close spatial proximity to the interaction interface with IL28RA ( Figure 6) . Supposed that the peptide blocks the interaction of the AB-loop of IFNL and IL28RA. The results of the competition LRA support this: The peptide has an inhibitory effect on the binding of all IFNLs, however the peptide is a more effective inhibitor of the interaction between IL28RA and either IFNL3 or IFNL2 than of the interaction of IFNL1 and IL28A. As expected, the peptide blocks the binding of IFNL3 most effectively since it occupies exactly the same binding pocket as the AB-loop of IFNL3.
As shown in Table 3 , the AB-loops of IFNL1 and IFNL2 aligned to the blocking peptide differ. Consistent with the lower IC 50 value of the peptide for inhibition of the IFNL1/IL28RA interaction, twelve amino acids differ between IFNL1 and the peptide whereas and only two amino acids differ between IFNL2 and the peptide. This indicates that there are slightly different binding modes for interaction between the AB-loops of the IFNLs and IL28RA and predicts that peptides which mimic IFNL1 would be more effective at blocking the interaction between IFNl1 and IL28RA than the interaction between IFNL3 and IL28RA.
Further, the peptide is overall positively charged (four arginine and two lysine residues but only two aspartate residues) and computational analysis shows that the peptide has no defined secondary motifs. Due to its coiled, flexible structure the peptide might also bind to other regions of the receptor. This could potentially block glutamate and aspartate residues such as D118, which forms a salt bridge to stabilize the ligandreceptor complex (Figure 5B and 5C ). 
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